Medicenna Therapeutics Corp (MDNAF)

$MDNAF Uggh

$MDNAF will we touch the all time low this year ? Good chance

$MDNAF In an aggressive animal model of acute GvHD, MDNA209 was able to extend overall survival by 400 percent, reduce weight loss and improve clinical scores.

$MDNAF The number of pre-clinical assets they have in the hopper is insane ! (Pg 18-20) https://www.sedarplus.ca/csa-party/records/document.html?id=f16c534b01ff6ce331a77fe70bf48926459445ab1e08aeca14a53664be2dae32

$MDNAF Ticker is spastic. But at least it's green.

$MDNAF Why can't we have nice things going into the weekend?

$MDNAF we need to get back on NASDAQ.

$MDNAF I want to see in Q1 2026 just after Q4 data

$MDNAF thank's we needed good information. Data from this year end will be key for our future

$MDNAF “Encouraged by previously reported data from each of the three tumor-specific cohorts, we are eager to develop MDNA11 via expedited regulatory routes to address unmet needs for patients who do not benefit from block-buster immunotherapies.”

$MDNAF “MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® at medical conferences and a planned KOL event”

$MDNAF “MDNA11 Phase 2b development plan to be solidified by end of calendar year, including evaluation of strategies for accelerated approval”

$MDNAF Medicenna Therapeutics reports FY25 EPS (15c) vs. (37c) last year "We are delighted to announce that the first MDNA11 monotherapy responder, a pancreatic cancer patient who had failed multiple lines of therapy including a checkpoint inhibitor, continues to be in remission for at least 18 months without any further treatment. Complete and partial responses in nine other patients in mono- and combination arms demonstrates best-in-class potential of MDNA11 amongst competing IL-2 programs," said Fahar Merchant, Ph.D., President and CEO of Medicenna. "We plan to complete enrollment in the Phase 1/2 ABILITY-1 trial and report top-line data from both monotherapy and combination arms before the end of this year. Encouraged by previously reported data from each of the three tumor-specific cohorts, we are eager to develop MDNA11 via expedited regulatory routes to address unmet needs for patients who do not benefit from block-buster immunotherapies. We are also excited with the progress we are making with our lead candidate from our proprietary BiSKIT platform, MDNA113, a bi-functional anti-PD1-IL2 Superkine that has built-in targeting and stealth capabilities allowing tumor localization and activation while concealing its peripheral activity. The design of MDNA113 addresses many safety issues associated with the current slate of high-profile bi-specific anti-PD1 candidates without compromising its efficacy in aggressive and immunologically "cold" tumors. We look forward to providing additional updates in the second half of 2025 at medical conferences as well as the planned KOL event."

$MDNAF LETS GO!

$MDNAF Year-end should be this week. Wonder if we’ll get a little juice with it?

$MDNAF straight to 0.3$

$MDNAF You're killing me, Smalls!

$MDNAF Fahar, could we please pull off an RGC? 🥹Just the 3 month chart would be A-OK 😌

$MDNAF chinese get deal and us get fuckt

$MDNAF so the last two presentations were announced on a cheesy X account with 500 followers instead of being officialy PR'ed well in advance. They better be in late stage acquisition talks to justify such sloppy communication

$MDNAF I doubt there is news this week, just their regular sales pitch…